IMMUNEERING EXPANDS ONCOLOGY SCIENTIFIC ADVISORY BOARD WITH EXPERTS IN KEY CANCER SIGNALING PATHWAY
25 mars 2020 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the addition of three leading oncology experts to the company’s Scientific Advisory Board (SAB). The new...
Immuneering Raises $20 Million in Oversubscribed Series A Funding
22 janv. 2020 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced that it has closed its oversubscribed Series A round at a total of $20 million. This new total reflects...
Immuneering Strengthens Executive Team With Appointment of Howard L. Kaufman, M.D., as Head of Research and Development
09 janv. 2020 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced an addition to its executive leadership team with the appointment of Howard L. Kaufman, M.D., FACS, as...
Immuneering Appoints Scott Barrett, M.D., as Chief Medical Officer
19 déc. 2019 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the appointment of Scott Barrett, M.D., as chief medical officer. Dr. Barrett brings nearly three decades...
Immuneering Completes $17 Million Series A Financing
16 déc. 2019 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the completion of a $17 million Series A financing. The financing was led by Boxcar PMJ LLC. Concurrent...
Immuneering to Present at the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting
04 déc. 2019 12h35 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Immuneering today announced the company’s participation in the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting taking...